RemeGen Co Ltd, a leading biopharmaceutical company, is guided by a strong set of values and corporate philosophy. With a focus on innovation, RemeGen strives to develop and deliver high-quality and cutting-edge therapies to improve the lives of patients. Their commitment to integrity and ethical practices forms the foundation of their operations. RemeGen embraces a patient-centric approach, ensuring that their products address significant medical needs and contribute to the well-being of individuals. By fostering collaboration and nurturing talent, RemeGen places great importance on teamwork and continuous learning. With these values and corporate philosophy, RemeGen Co Ltd remains dedicated to making a positive impact in the healthcare industry.

RemeGen Co Ltd is primarily present in China.

RemeGen Co Ltd has achieved several significant milestones in its journey. Firstly, the company successfully developed three innovative antibody-based drugs targeting cancer and autoimmune diseases. This breakthrough in biopharmaceutical research highlights RemeGen's commitment to advancing medical treatments. Additionally, the company gained approval for its leading drug, RC48, to treat metastatic or locally recurrent triple-negative breast cancer, a major accomplishment in the field. Moreover, RemeGen forged strategic partnerships with top global pharmaceutical companies, fostering collaborations for research, development, and commercialization of its drugs. These milestones underscore RemeGen Co Ltd's dedication to revolutionizing healthcare and cement its position as a trusted leader in the industry.

RemeGen Co Ltd is a renowned biopharmaceutical company founded in 2008, headquartered in Yantai, China. With a focus on research, development, and commercialization of innovative therapies, RemeGen has made significant strides in the field of oncology. The company aims to address unmet medical needs and revolutionize treatment options for patients worldwide. RemeGen Co Ltd has earned recognition for its robust pipeline of potential breakthrough drugs, leveraging their expertise in monoclonal antibodies, antibody-drug conjugates, and fusion proteins. Their commitment to scientific excellence and dedication to improving patients' lives have established RemeGen as a leading player in the biopharmaceutical industry.

The main competitors of RemeGen Co Ltd in the market include a range of pharmaceutical companies operating in the same sector. Some notable competitors include BeiGene Ltd, Hengrui Medicine Co Ltd, and Junshi Biosciences Co Ltd. These companies, like RemeGen Co Ltd, are engaged in the research, development, and commercialization of innovative drugs and therapies. As a leading player in the pharmaceutical industry, RemeGen Co Ltd competes in various therapeutic areas, aiming to bring novel and effective treatments to the market.

RemeGen Co Ltd is primarily active in the pharmaceutical industry.

RemeGen Co Ltd is a biopharmaceutical company based in China. The business model of RemeGen Co Ltd primarily focuses on the research, development, and commercialization of innovative biologics for the treatment of various diseases. The company specializes in developing monoclonal antibodies and fusion proteins to target specific diseases, such as cancer and autoimmune disorders. RemeGen Co Ltd aims to provide effective and safe therapeutic options to patients in need, while also generating sustainable growth and creating value for its shareholders. With its dedication to advancing healthcare through biotechnology, RemeGen Co Ltd strives to positively impact patients' lives and contribute to the advancement of the global pharmaceutical industry.

Коефициентът на цена спрямо печалбата (КЦП) на RemeGen Co е -5,59.

Коефициентът на цена към оборот (KUV) на RemeGen Co е 4,81.

AlleAktien качественият резултат за RemeGen Co е 3/10.

очаквана RemeGen Co оборотът е 1,67 млрд. CNY.

очаквана RemeGen Co печалба е -1,44 млрд. CNY.

The company RemeGen Co Ltd is a biopharmaceutical company based in China that specializes in the development and commercialization of novel therapeutic antibodies. The company was founded in 2008 and is one of the leading companies in the biopharmaceutical industry. RemeGen is working on the development of antibodies with high efficacy and low risk of side effects. The company has developed a comprehensive pipeline that includes clinical trials for a variety of diseases, including cancer, autoimmune diseases, viral infections, and inflammation. The company's main product is IBI310, a monoclonal antibody specifically designed for the treatment of cancer patients. IBI310 fights cancer cells by selectively binding to the surface protein PD-L1 and triggering an immune response that destroys the cancer cells. The drug has the potential to revolutionize the treatment of cancer patients and is already being tested in clinical trials. RemeGen also offers projects in the field of novel antibody therapy for autoimmune diseases. The company has developed a pipeline of several potential therapeutics targeting various target molecules involved in autoimmune diseases. The company is also focused on the development of drugs to combat viral infections such as hepatitis B and C, as well as HIV. RemeGen's goal is to defeat these diseases and provide patients with a better quality of life. RemeGen is also a leading provider of biopharmaceutical services that support customers in conducting their research and product development. The company offers a wide range of services ranging from antibody design and development to cell line development and production, as well as analysis and characterization. RemeGen's business model is based on collaboration with other biopharmaceutical companies to jointly develop more innovative and effective therapies. The company has established strong partnerships with leading pharmaceutical companies such as Pfizer, Merck, and Roche. RemeGen's experience and expertise in the field of biopharmaceutical research and development have contributed to its position as one of the leading companies in this field. The company is continuously working to improve medical care and enhance the quality of life for patients.

RemeGen Co разпределя дивидента от 0 CNY на плащания годишно.

Дивидентата за RemeGen Co в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на RemeGen Co е CNE1000048G6.

WKN на RemeGen Co е A2QGM4.

Тикерът на RemeGen Co е 9995.HK.

През последните 12 месеца RemeGen Co изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква RemeGen Co да изплати дивиденда в размер на 0 CNY.

Дивидентната доходност на RemeGen Co в момента е .

RemeGen Co изплаща дивидент на тримесечие. Той се разпределя в месеците .

RemeGen Co платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 CNY. Това съответства на дивидентна доходност от 0 %.

RemeGen Co се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от RemeGen Co на 17.12.2024 г. в размер на 0 CNY, трябваше да притежавате акцията в портфейла си преди Ex-деня на 17.12.2024 г..

Последното дивидентно плащане беше извършено на 17.12.2024 г..

През година 2023 RemeGen Co изплати 0 CNY под формата на дивиденти.

Дивидентите от RemeGen Co се изплащат в CNY.